Solving Healthcare's Hemodynamic Blind Spot: Quantitative Blood Volume Analysis and Inpatient Heart Failure Optimization
Dr. Dereck Mush, MD, MBA
NextGen Jane
Genomics company analyzing endometrial tissue and menstrual blood for reproductive health.
What they do
The company utilizes custom collection tampons to gather menstrual blood for clinical analysis. By tracking genomic markers in shed endometrial tissue, the technology aims to identify conditions such as endometriosis and uterine fibroids non-invasively, providing a diagnostic alternative to laparoscopy.
The record
- Vertical
- Women's Health
- Sub-segment
- Menstrual blood diagnostics
- Product type
- Diagnostics
- Stage
- Series A
- Headquarters
- Oakland, USA
- Region
- North America
- Founded
- 2014
- Total funding
- $9M raised
Notable investors: Material Impact, Viking Global Investors, Jane Martin.
Also in Women's Health
Related on The Signal
Dr. Dereck Mush, MD, MBA
Cardiometabolic prevention platforms are targeting the decade men spend ignoring warning signs
Dr. Dereck Mush, MD, MBA
The First OTC Cuffless Blood Pressure Wearable Just Cleared FDA. Can It Replace the Cuff
Dr. Dereck Mush, MD, MBA
Top 25 Cardiologists to Follow on LinkedIn in 2026
Dr. Dereck Mush, MD, MBA